Navigation Links
Antibiotic treats lymphoma of the eye

The common antibiotic doxycycline effectively treats a type of lymphoma associated with chlamydia infection, according to a study in the October 4 issue of the Journal of the National Cancer Institute.

Ocular adnexal lymphoma of the MALT-type (OAL) is a kind of cancer of the eyelids and related tissues. It is not often fatal, but its symptoms can compromise a patient's quality of life. Some research has suggested an association between OAL and infection with the bacteria Chlamydia psittaci.

Andres J. M. Ferreri, M.D., of the San Raffaele H Scientific Institute in Milan, Italy, and colleagues examined whether doxycycline was an effective treatment for OAL. They gave 27 OAL patients a 3-week course of doxycycline therapy, whether they were positive or negative for chlamydia. They looked for tumor progression every 6 months.

The authors found that doxycycline treatment caused lymphoma to regress in both patients who did not test positive for the disease and those who did. They suggest that doxycycline may be a useful therapy even in patients where other treatments have failed, and it is a valid alternative to chemotherapy and radiation without causing the same toxic side-effects. Patients treated with doxycycline had a 66% rate of disease-free survival.

"Our prospective trial revealed that doxycycline is a fast, safe, and active treatment for OAL, both at initial diagnosis and at relapse," the authors write.

In an accompanying editorial, Emanuel Zucca, M.D., and Francesco Bertoni, M.D., of the Oncology Institute of Southern Switzerland, write, "While doxycycline appears to be an easy-to-implement therapeutic approach, we strongly encourage all physicians to enroll patients in clinical prospective trials to help answer these questions."


'"/>

Source:Journal of the National Cancer Institute


Page: 1

Related biology news :

1. Antibiotic Resistant Bacterium Uses Sonar-like Strategy to “See?Enemies or Prey
2. Antibiotic might fight HIV-induced neurological problems
3. New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal
4. To Stop Evolution: New Way Of Fighting Antibiotic Resistance Demonstrated By Scripps Scientists
5. Chemical Engineer Kao Explores Antibiotic Synthesis With DNA Chips
6. Use of Antibiotics for Acne May Increase Risk of Common Illness
7. Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance
8. Antibiotic inhibits cancer gene activity
9. Antarctic ice shelf retreats happened before
10. Stem cell therapy successfully treats heart attack in animals
11. Gene therapy advance treats hemophilia in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
(Date:1/18/2017)... 2017  In vitro diagnostic (IVD) companies were very ... (M&A), and Kalorama Information expects that trend to continue ... shifting. Generally, uncertainty in reimbursement and healthcare reform in ... changed the acquisitions landscape. Instead of looking to buy ... partners outside of their home country and also to ...
(Date:1/13/2017)... PORT WASHINGTON, N.Y. , Jan. 13, 2017 ... provider of technology solutions for the homecare industry, ... appointment of homecare industry expert, Justin Jugs, as ... Justin brings more than 15 years of homecare ... the team in developing strategic plans to align ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies ... Marbán, Ph.D, president and chief executive officer, is scheduled to ... Cowen and Company 37th Annual Health Care Conference Tuesday, March ... 29th Annual ROTH Conference Tuesday, ... Dana Point, CA ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 ... company, and Beyond Type 1, a not-for-profit advocacy and ... today announced a grant from Beyond Type 1 to ... type 1 and other insulin-requiring diabetes.  ... innovative stem cell-derived cell replacement therapies with a focus ...
(Date:2/22/2017)... Kan. , Feb. 22, 2017  Aratana Therapeutics, Inc. ... development and commercialization of innovative biopharmaceutical products for companion animals, ... 2017 at 8:30 a.m. ET to discuss financial results from ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in ... for all SPIE attendees and Park customers on Feb. 27, 2017 from ... San Jose Convention Center. The luncheon will feature a talk on Automated AFM ...
Breaking Biology Technology: